Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- Japan Mulls Securing AstraZeneca COVID Cocktail If Approved: Minister
June 13, 2022
- Japan Confirms 11 More Probable Cases of Acute Hepatitis in Children
June 13, 2022
- Pharma Wants Govt Purchase for Novel Antimicrobial, Instead of Favorable Pricing
June 10, 2022
- “Re-Do” Pricing Based on New Assumption Rather than Simple Cuts, DPP Lawmaker Says on Re-Pricing Rules
June 10, 2022
- MHLW Council OKs Public Knowledge-Based Applications for 3 Drugs Including Acetaminophen
June 9, 2022
- Edurant Label Revised for Combined Use with Vocabria
June 8, 2022
- Japan OKs Honebuto Paper with No Mention of Drug Pricing; Stable Supply, Innovation, Biosimilar Promotion Spelled Out
June 8, 2022
- AMED Sets to Lay R&D Data Utilization Infrastructure from Current Fiscal Year
June 8, 2022
- Pharmacist LDP Candidate Eager for National Debate on Drug Pricing
June 7, 2022
- Public-Private Confab Set for June 14, Talks on Data Utilization Expected
June 7, 2022
- Scrap All Barriers, Annual Drug Re-Pricing to Boost International Competitiveness of Japan Pharma: LDP’s Jimi
June 6, 2022
- Japan Govt to Set Biosimilar Target by March 2023: Honebuto Draft
June 6, 2022
- Japan Reports 5 More Probable Cases of Acute Hepatitis in Children
June 6, 2022
- MHLW Panel Endorses Sanofi’s Sutimlimab as Japan’s First CAD Therapy
June 3, 2022
- LDP Pharma Study Group Prods Rethink of Annual Re-Pricing, but Health Minister Sounds Negative
June 3, 2022
- MHLW Panel OKs 62 More Health Damage Claims for COVID-19 Vaccines
June 3, 2022
- Working Group Urges Govt to Discuss Use of Anonymized Medical Data for Regulatory Purposes
June 2, 2022
- Panel OKs Orphan Designation for Pfizer’s Hemophilia Gene Therapy
June 2, 2022
- Honebuto Draft Fails to Clear LDP, Renewed Discussions Set for June 3
June 2, 2022
- Govt’s Draft Grand Design for New Capitalism Vows to Spur Biotechnology Innovation
June 1, 2022
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…